Levomine (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol is a synthetic estrogen that suppresses the mid‑cycle surge of luteinizing hormone, while levonorgestrel is a progestin that blocks the luteinizing hormone surge and prevents follicular development. Together they stop ovulation, thicken cervical mucus, and alter the endometrium, making implantation unlikely.

The dosage of Levomine is determined by the prescribing clinician based on the product’s labeling and the patient’s individual needs. Typically, the medication is taken once daily at the same time for a 21‑day active phase followed by a hormone‑free interval, but the exact regimen must be confirmed by a qualified health professional.

Levomine is contraindicated during pregnancy because its hormonal components can affect fetal development. Women who become pregnant while taking the product should discontinue use immediately. Breastfeeding is not recommended while on combined oral contraceptives, as the hormones may pass into breast milk and affect the infant; alternative methods should be considered.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levomine contains a standard dose of ethinylestradiol paired with levonorgestrel, a widely used progestin. Compared with formulations that use newer progestins, Levomine offers a well‑characterized safety profile and reliable contraceptive efficacy. Choice of product often depends on individual risk factors, tolerability, and physician preference.

Levomine tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Levomine is taken orally, usually as one tablet each day, at the same time each day. The typical regimen includes 21 consecutive days of active tablets followed by a 7‑day hormone‑free interval, during which withdrawal bleeding occurs. Patients should follow the specific instructions provided by their healthcare provider.

The most serious risks include venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism, arterial thrombosis leading to stroke or myocardial infarction, and severe hypertension. Women with a history of clotting disorders, smoking, or certain cardiovascular conditions should avoid Levomine and discuss alternatives with their clinician.

Levomine is contraindicated in women who are pregnant, have known or suspected estrogen‑dependent tumors, a history of thromboembolic disease, uncontrolled hypertension, active liver disease, or who are breastfeeding. It should also be avoided in individuals with known hypersensitivity to ethinylestradiol, levonorgestrel, or any tablet excipients.